Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma

Liver Transplantation

Volumn 20, Issue 3, 2014, Pages 291-297

  Tsuchiya, Kaoru ^a,b   Asahina, Yasuhiro ^c   Tamaki, Nobuharu ^a   Yasui, Yutaka ^a   Hosokawa, Takanori ^a   Ueda, Ken ^a   Nakanishi, Hiroyuki ^a,b   Itakura, Jun ^a   Kurosaki, Masayuki ^a   Enomoto, Nobuyuki ^b   Izumi, Namiki ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CHILD PUGH SCORE; EARLY CANCER; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MILAN CRITERIA; NON INVASIVE PROCEDURE; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RISK FACTOR; SCORING SYSTEM; SURVIVAL RATE;

AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84896699731     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23798     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF Jr,. International trends and patterns of primary liver cancer. Int J Cancer 2001; 94: 290-296.
3. Bruix J, Sherman M,; for American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
5. Leung JY, Zhu AX, Gordon FD, Pratt DS, Mithoefer A, Garrigan K, et al. Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl 2004; 10: 1343-1354.
6. Mazzaferro V, Chun YS, Poon RT, Schwartz ME, Yao FY, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol 2008; 15: 1001-1007.
7. Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005; 103: 1201-1209.
8. Teratani T, Yoshida H, Shiina S, Obi S, Sato S, Tateishi R, et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology 2006; 43: 1101-1108.
9. Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005; 41: 1130-1137.
10. Chan AC, Chan SC, Chok KS, Cheung TT, Chiu DW, Poon RT, et al. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? Liver Transpl 2013; 19: 411-419.
11. Llovet JM, Brú C, Bruix J,. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
12. Asahina Y, Nakanishi H, Izumi N,. Laparoscopic radiofrequency ablation for hepatocellular carcinoma. Dig Endosc 2009; 21: 67-72.
13. Vivarelli M, Guglielmi A, Ruzzenente A, Cucchetti A, Bellusci R, Cordiano C, Cavallari A,. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg 2004; 240: 102-107.
14. Guglielmi A, Ruzzenente A, Valdegamberi A, Pachera S, Campagnaro T, D'Onofrio M, et al. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 2008; 12: 192-198.
15. Cho CM, Tak WY, Kweon YO, Kim SK, Choi YH, Hwang YJ, Kim YI,. The comparative results of radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma [in Korean]. Korean J Hepatol 2005; 11: 59-71.
16. Ogihara M, Wong LL, Machi J,. Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes. HPB (Oxford) 2005; 7: 214-221.
17. Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M, et al. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol 2008; 49: 589-594.
18. Cucchetti A, Piscaglia F, Cescon M, Colecchia A, Ercolani G, Bolondi L, Pinna AD,. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 2013; 59: 300-307.
19. Llovet JM, Schwartz M, Mazzaferro V,. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181-200.
20. Tsuchiya K, Komuta M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, et al. Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation. Oncology 2011; 80: 278-288.
21. Ziol M, Sutton A, Calderaro J, Barget N, Aout M, Leroy V, et al. ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. J Hepatol 2013; 59: 1264-1270.
22. Tateishi R, Shiina S, Yoshida H, Teratani T, Obi S, Yamashiki N, et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 2006; 44: 1518-1527.
23. Yamashiki N, Tateishi R, Yoshida H, Shiina S, Teratani T, Sato S, et al. Ablation therapy in containing extension of hepatocellular carcinoma: a simulative analysis of dropout from the waiting list for liver transplantation. Liver Transpl 2005; 11: 508-514.
24. Parfitt JR, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin NG, et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl 2007; 13: 543-551.
25. Takada Y, Ueda M, Ito T, Sakamoto S, Haga H, Maetani Y, et al. Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl 2006; 12: 912-919.